Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

Human papillomavirus type 16 L1 capsid protein residues 2–471 antigen is a recombinant form of the major structural (L1) protein from high-risk human papillomavirus (HPV) type 16. This recombinant antigen self-assembles into virus-like particles (VLPs), which closely mimic the structure of native virions but lack viral DNA and are non-infectious. These VLPs are highly immunogenic and serve as the active component in prophylactic vaccines such as Cervarix for prevention of cervical cancer and other diseases caused by oncogenic HPVs. The mechanism of action involves induction of neutralizing antibodies that prevent initial infection by targeting conformational epitopes on the viral surface[6][7][8]. The primary developer and manufacturer is GlaxoSmithKline (GSK)[6]. Other companies such as Serum Institute of India and Bharat Biotech have also developed or are developing similar vaccines using this technology[5].

Brand names

Cervarix

Other names

HPV-16 L1 VLPHPV16 L1 VLPHPV 16 L1 VLPHPV-16 virus-like particleHPV16 virus-like particleHPV 16 virus-like particleHPV-16 major capsid protein VLPHPV16 major capsid protein VLPHPV 16 major capsid protein VLPHPV-16 outer capsid protein VLPHPV16 outer capsid protein VLPHPV 16 outer capsid protein VLPHPV-16 structural protein VLPHPV16 structural protein VLPHPV 16 structural protein VLPHPV-16 L1 assembly VLP[3][6]